{"id":"meningococcal-diphtheria-toxoid-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine uses a conjugate approach in which meningococcal capsular polysaccharides are chemically linked to diphtheria toxoid as a carrier protein. This conjugation enhances the immunogenicity of the polysaccharide antigens and promotes a robust T-cell dependent immune response, resulting in durable antibody production and immunological memory against Neisseria meningitidis.","oneSentence":"This vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide antigens conjugated to diphtheria toxoid, providing protection against meningococcal disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:20:45.163Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of meningococcal disease caused by Neisseria meningitidis"}]},"trialDetails":[{"nctId":"NCT04006457","phase":"PHASE3","title":"Long-Term PF-06651600 for the Treatment of Alopecia Areata","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2019-07-18","conditions":"Alopecia Areata","enrollment":1052},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":"Diarrhoea","enrollment":528},{"nctId":"NCT05073003","phase":"PHASE1","title":"A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-10-06","conditions":"Diarrhoea","enrollment":551},{"nctId":"NCT05480800","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-09-13","conditions":"Salmonella Infections","enrollment":155},{"nctId":"NCT04368429","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-05-22","conditions":"Meningococcal Immunisation (Healthy Volunteers)","enrollment":360},{"nctId":"NCT04490018","phase":"PHASE3","title":"Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2021-03-16","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":463},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT03295318","phase":"PHASE2","title":"Clinical Study of Meningococcal ACYWX Conjugate Vaccine, in 12-16 Month Olds","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2017-11-15","conditions":"Meningitis, Meningococcal","enrollment":375},{"nctId":"NCT05093829","phase":"PHASE3","title":"Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate Vaccine","status":"COMPLETED","sponsor":"Emory University","startDate":"2022-03-24","conditions":"Meningitis","enrollment":1325},{"nctId":"NCT06131554","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2024-03-20","conditions":"Meningococcal Meningitis","enrollment":1480},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT04143061","phase":"PHASE3","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2019-12-30","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":1328},{"nctId":"NCT03917654","phase":"PHASE2","title":"Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escalation Trial of Children and a Family Compound Trial in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-04-24","conditions":"Malaria","enrollment":1301},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT04450498","phase":"PHASE4","title":"A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years","status":"COMPLETED","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2020-12-23","conditions":"Neisseria Meningitides Meningitis","enrollment":260},{"nctId":"NCT05298644","phase":"PHASE2, PHASE3","title":"COVID-19 Paediatric VLA2001-321 Study","status":"WITHDRAWN","sponsor":"Valneva Austria GmbH","startDate":"2022-10-01","conditions":"SARS-CoV-2 Infection","enrollment":""},{"nctId":"NCT02324751","phase":"PHASE2","title":"Vaccines Against Salmonella Typhi","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2015-09","conditions":"Typhoid Fever, Enteric Fever","enrollment":112},{"nctId":"NCT02699840","phase":"","title":"Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-02","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":100},{"nctId":"NCT02864927","phase":"PHASE4","title":"Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-21","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1311},{"nctId":"NCT01890759","phase":"PHASE3","title":"Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-06-25","conditions":"Meningitis, Meningococcal Infection","enrollment":300},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT02752906","phase":"PHASE3","title":"Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-04-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":810},{"nctId":"NCT02842853","phase":"PHASE3","title":"Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-07-15","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":3344},{"nctId":"NCT02199691","phase":"PHASE2","title":"Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2014-07-22","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1715},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT03077438","phase":"PHASE3","title":"Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-02-17","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":1000},{"nctId":"NCT01187433","phase":"PHASE2","title":"Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-08","conditions":"Dengue, Dengue Hemorrhagic Fever","enrollment":150},{"nctId":"NCT00459316","phase":"PHASE1, PHASE2","title":"Safety of and Immune Response to a Meningitis Vaccine in HIV-Infected Children and Youth","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2007-06","conditions":"HIV Infections, Meningitis","enrollment":384},{"nctId":"NCT04358731","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Lot to Lot Consistency of SIIPL Meningococcal ACYWX Conjugate Vaccine and to Compare Its Safety and Immunogenicity With That of Licensed Meningococcal ACWY Vaccine Menactra® in Healthy Individuals 18-85 Years of Age","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-12-27","conditions":"Vaccine for Meningococcal Disease","enrollment":1640},{"nctId":"NCT04204096","phase":"PHASE3","title":"Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)","status":"COMPLETED","sponsor":"International Vaccine Institute","startDate":"2020-02-04","conditions":"Typhoid","enrollment":1800},{"nctId":"NCT03964012","phase":"PHASE3","title":"Study to Assess Immunegnicity & Safety of Pentavalent Meningococcal Vaccine (NmCV-5)","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2019-08-20","conditions":"Meningococcal Meningitis","enrollment":1800},{"nctId":"NCT02810340","phase":"PHASE1","title":"Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2016-08-01","conditions":"Meningococcal Vaccines","enrollment":60},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00228917","phase":"PHASE3","title":"Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-06-16","conditions":"Whole Cell Pertussis, Tetanus, Hepatitis B","enrollment":798},{"nctId":"NCT01430689","phase":"PHASE4","title":"Maternal Flu Vaccine Trial in Bamako, Mali","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2011-09-12","conditions":"Influenza","enrollment":4193},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT02275741","phase":"","title":"Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis","status":"COMPLETED","sponsor":"Dr. med. Micha Loebermann","startDate":"2009-10","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":226},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT02002156","phase":"PHASE4","title":"A Study of the Interaction Between BCG And MenC Immunisation: BAM","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2014-06-20","conditions":"BCG Infection, Reaction - Vaccine, Immune Response","enrollment":28},{"nctId":"NCT02858570","phase":"PHASE2, PHASE3","title":"Conjugate Vaccine Against Meningococcus C a Brazilian Project","status":"UNKNOWN","sponsor":"The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)","startDate":"2018-09-25","conditions":"Serogroup C Meningococcal Meningitis","enrollment":1644},{"nctId":"NCT00310856","phase":"PHASE2","title":"Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2005-06","conditions":"Meningococcal Meningitis","enrollment":175},{"nctId":"NCT00614614","phase":"PHASE3","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-02-13","conditions":"Infections, Meningococcal","enrollment":1558},{"nctId":"NCT00282295","phase":"PHASE4","title":"US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-25","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":1344},{"nctId":"NCT01867463","phase":"PHASE1","title":"Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2013-03-27","conditions":"Malaria","enrollment":230},{"nctId":"NCT00871338","phase":"PHASE2","title":"Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06-24","conditions":"Neisseria Meningitidis, Haemophilus Influenzae Type b","enrollment":284},{"nctId":"NCT02640404","phase":"PHASE2","title":"Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-06-06","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":224},{"nctId":"NCT02591290","phase":"PHASE4","title":"Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-10-20","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":60},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT01767376","phase":"PHASE3","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2013-01-10","conditions":"Infections, Meningococcal","enrollment":692},{"nctId":"NCT00856297","phase":"PHASE3","title":"Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-02","conditions":"Meningococcal Meningitis","enrollment":389},{"nctId":"NCT02097849","phase":"PHASE2","title":"Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.","status":"COMPLETED","sponsor":"Biogen","startDate":"2015-02-28","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":71},{"nctId":"NCT00289913","phase":"PHASE4","title":"Concomitant Use of Hepatitis A Vaccine, Inactivated With Haemophilus b Conjugate Vaccine (Meningococcal Protein Conjugate) and Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Given to Healthy Children 15 Months of Age (V251-068)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-04","conditions":"Hepatitis A Virus","enrollment":1274},{"nctId":"NCT01689155","phase":"","title":"Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-06","conditions":"Meningitis, Meningococcal Infection","enrollment":116},{"nctId":"NCT02633787","phase":"PHASE4","title":"Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2015-12","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":110},{"nctId":"NCT01359449","phase":"PHASE3","title":"Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-05","conditions":"Meningitis, Meningococcal Infection","enrollment":123},{"nctId":"NCT00518180","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Conjugate Vaccine In Adolescents","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Meningitis, Human Papillomavirus Infection, Pertussis","enrollment":1620},{"nctId":"NCT00483574","phase":"PHASE3","title":"Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-05","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1378},{"nctId":"NCT00254995","phase":"","title":"Descriptive, Post-marketing, Surveillance Safety Study of Menactra Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-07","conditions":"Meningitis, Meningococcal Disease","enrollment":62626},{"nctId":"NCT00539032","phase":"PHASE3","title":"Immunology and Safety of Menactra® in Children in Saudi Arabia","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-09","conditions":"Meningitis, Meningococcemia","enrollment":238},{"nctId":"NCT00700635","phase":"PHASE2","title":"Dose Comparison Study of Menactra® in US Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Meningitis, Meningococcal Infection, Neisseria Meningitidis","enrollment":333},{"nctId":"NCT00771849","phase":"PHASE2","title":"Study of Antibody Responses After a Dose of Tetravalent Meningococcal Diphtheria Conjugate Vaccine in Children","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-08","conditions":"Meningitis, Meningococcemia","enrollment":103},{"nctId":"NCT00269477","phase":"PHASE2","title":"Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-12","conditions":"Meningitis, Meningococcal Infection","enrollment":145},{"nctId":"NCT00384397","phase":"PHASE3","title":"A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-09","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1128},{"nctId":"NCT00422292","phase":"PHASE3","title":"Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-12","conditions":"Meningococcal Meningitis, Measles, Mumps","enrollment":1664},{"nctId":"NCT02500511","phase":"","title":"Persistence of Protective Antibody Titers 12-24 Months After NmVac4-A/C/Y/W-135-DT Vaccination: Follow Up Study","status":"COMPLETED","sponsor":"JN-International Medical Corporation","startDate":"2015-06","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":50},{"nctId":"NCT00700713","phase":"PHASE2","title":"Antibody Persistence and Booster Dose Response in Subjects Who Received Menactra® Three Years Earlier in Study MTA26","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-06","conditions":"Meningitis, Meningococcemia","enrollment":181},{"nctId":"NCT01659996","phase":"PHASE4","title":"Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-07","conditions":"Meningitis, Meningococcal Infection, Diphtheria","enrollment":1394},{"nctId":"NCT00381615","phase":"PHASE2","title":"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Healthy","enrollment":147},{"nctId":"NCT00444951","phase":"PHASE3","title":"Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-02","conditions":"Neisseria Meningitidis, Meningococcal Infections","enrollment":450},{"nctId":"NCT01897402","phase":"PHASE2","title":"Immunogenicity and Safety of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine","status":"COMPLETED","sponsor":"JN-International Medical Corporation","startDate":"2013-07","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":525},{"nctId":"NCT00728260","phase":"","title":"36-Month Post-marketing Surveillance and Analysis of Menactra Vaccine in 2-10 Year Olds","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-07","conditions":"Meningitis, Meningococcal Disease","enrollment":1421},{"nctId":"NCT01367158","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-07","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":440},{"nctId":"NCT01442675","phase":"PHASE2","title":"Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2011-09","conditions":"Meningitis, Meningococcal Infection","enrollment":834},{"nctId":"NCT01270503","phase":"PHASE4","title":"Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-12","conditions":"Meningitis, Meningococcal Disease","enrollment":538},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT00262002","phase":"PHASE2","title":"Study of the Safety and Immune Response of a Meningococcal Vaccine Administered to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2004-09","conditions":"Prevention of Meningococcal Disease","enrollment":601},{"nctId":"NCT01000311","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2009-11","conditions":"Meningococcal Disease","enrollment":529},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT00777790","phase":"PHASE2","title":"Study of a Booster Dose of Meningococcal Diphtheria Toxoid Conjugate Vaccine in Adolescents","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-02","conditions":"Meningitis, Meningococcemia","enrollment":241},{"nctId":"NCT00772070","phase":"PHASE2","title":"Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjugate Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2003-03","conditions":"Meningitis, Meningococcemia, Neisseria Meningitidis","enrollment":173},{"nctId":"NCT00258856","phase":"PHASE2","title":"Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune®","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2006-01","conditions":"Meningitis, Meningococcal Infection","enrollment":234},{"nctId":"NCT00772629","phase":"PHASE2","title":"Antibody Responses Following Meningococcal Tetravalent (A, C, Y, and W-135) Conjugate Vaccination in Healthy Adults","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-01","conditions":"Meningitis, Meningococcemia","enrollment":18},{"nctId":"NCT00643916","phase":"PHASE2","title":"Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2004-12","conditions":"Meningitis, Meningococcal Infection","enrollment":378},{"nctId":"NCT00777257","phase":"PHASE4","title":"Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2005-04","conditions":"Meningitis, Meningococcemia, Pertussis","enrollment":1345},{"nctId":"NCT01642589","phase":"PHASE3","title":"Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-07","conditions":"Meningitis, Meningococcal Disease","enrollment":300},{"nctId":"NCT00874549","phase":"PHASE1, PHASE2","title":"Exploratory Trial to Evaluate the Safety and Immunogenicity of Menactra® and Menomune® Vaccines in Subjects ≥ 56 Years","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2007-10","conditions":"Meningococcal Infections, Meningococcal Meningitis","enrollment":216},{"nctId":"NCT01519713","phase":"PHASE3","title":"Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2012-01","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":200},{"nctId":"NCT01482052","phase":"PHASE1","title":"Safety Study of Group A, C, Y & W-135 Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine for Meningitis","status":"COMPLETED","sponsor":"JN-International Medical Corporation","startDate":"2011-11","conditions":"Meningococcal Meningitis, Meningococcal Infections","enrollment":60},{"nctId":"NCT01239043","phase":"PHASE2","title":"Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-11","conditions":"Meningitis, Meningococcal Meningitis, Meningococcal Infections","enrollment":139},{"nctId":"NCT01086969","phase":"PHASE3","title":"A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India","status":"COMPLETED","sponsor":"Sanofi","startDate":"2010-06","conditions":"Meningococcal Infection, Meningitis","enrollment":300},{"nctId":"NCT00355121","phase":"PHASE2","title":"Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Meningococcal Meningitis, Tetanus, Diphtheria","enrollment":882}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Menactra®"],"phase":"phase_3","status":"active","brandName":"Meningococcal Diphtheria Toxoid Vaccine","genericName":"Meningococcal Diphtheria Toxoid Vaccine","companyName":"Sanofi Pasteur, a Sanofi Company","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies against meningococcal polysaccharide antigens conjugated to diphtheria toxoid, providing protection against meningococcal disease. Used for Prevention of meningococcal disease caused by Neisseria meningitidis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}